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BACKGROUND: Fine-needle aspiration cytology (FNAC) of serous membrane effusions may fulfil a challenging role in the
diagnostic analysis of both primary and metastatic disease. From this perspective, liquid-based cytology (LBC) represents
a feasible and reliable method for empowering the performance of ancillary techniques (ie, immunocytochemistry and
molecular testing) with high diagnostic accuracy. METHODS: In total, 3171 LBC pleural and pericardic effusions were
appraised between January 2000 and December 2013. They were classified as negative for malignancy (NM), suspicious
for malignancy (SM), or positive for malignancy (PM). RESULTS: The cytologic diagnoses included 2721 NM effusions
(2505 pleural and 216 pericardic), 104 SM effusions (93 pleural and 11 pericardic), and 346 PM effusions (321 pleural and
25 pericardic). The malignant pleural series included 76 unknown malignancies (36 SM and 40 PM effusions), 174 meta-
static lesions (85 SM and 89 PM effusions), 14 lymphomas (3 SM and 11 PM effusions), 16 mesotheliomas (5 SM and 11 SM
effusions), and 3 myelomas (all SM effusions). The malignant pericardic category included 20 unknown malignancies (5
SM and 15 PM effusions), 15 metastatic lesions (1 SM and 14 PM effusions), and 1 lymphoma (1 PM effusion). There were 411
conclusive immunocytochemical analyses and 47 molecular analyses, and the authors documented 88% sensitivity, 100%
specificity, 98% diagnostic accuracy, 98% negative predictive value, and 100% positive predictive value for FNAC.
CONCLUSIONS: FNAC represents a primary diagnostic tool for effusions and a reliable approach with which to determine
the correct follow-up. Furthermore, LBC is useful for ancillary techniques, such as immunocytochemistry and molecular
analysis, with feasible diagnostic and predictive utility. Cancer (Cancer Cytopathol) 2015;000:000-000. VC 2015 American
Cancer Society.
KEY WORDS: pericardic effusions; pleural effusions; liquid-based cytology; immunocytochemistry.
INTRODUCTION
The potential for cytologic evaluation of serous effusions has not been completely assessed to date, although there
recently has been increasing and growing interest.1–5 Recent data published by Lee et al indicate that 20% of body
serous membrane effusions per year are malignant: approximately 50% are diagnosed as metastatic adenocarcino-
mas followed by pulmonary large cell carcinoma and lymphomas/leukemias (approximately 15% each).1–3
Considering the challenging implications of the presence of malignant cells in effusions, an accurate cyto-
logic evaluation represents a critical and mainstream diagnostic tool, mostly because of its simplicity, safety, and
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cost effectiveness in reducing all of the possible conse-
quences and complications of a more aggressive biopsy
procedure, which often may fall short of obtaining
adequate diagnostic material.1–5 Furthermore, most pleu-
ral and pericardic effusions are associated with lung and
ovarian cancers, and their cytologic evaluation may play
an important role either in the initial diagnosis of patients
with symptomatic cancers or in patient management and
follow-up.1–5
The recognition of malignant cells as well as their
discrimination from reactive mesothelial cells requires the
ability to reproduce findings regardless of which methods
of preparation and cytology are used, including conven-
tional smears, cytospins, cell blocks, and liquid-based
cytology (LBC).1–8 The phenotype of reactive, nonmalig-
nant mesothelial cells can be misclassified as cancer;
accordingly, ancillary techniques are critical to obtain an
accurate diagnosis. Although different groups have
reported good results using each of these techniques, we
extensively use LBC as the primary method for the mor-
phologic evaluation of cytologic findings in effusions
(which also permits the use of residual sample to perform
complementary analyses) and fine-needle aspiration cytol-
ogy (FNAC) samples, as discussed below.1–8
In addition, a strong diagnostic aid in assessing cyto-
logic morphology is the increasing and accurate applica-
tion of ancillary techniques (both molecular testing and
immunocytochemistry [ICC]) to cytology, including
malignant effusions, with diagnostic and predictive
intent.9–14 Several groups have attempted to define the
best combination of immunomarkers for diagnosing effu-
sions, which has resulted in a lucky application of these
techniques for diagnostic, therapeutic, and prognostic
purposes, especially when LBC is adopted.5,15,16
LBC, which has been approved by the US Food and
Drug Administration since 1996 (and was originally
developed for cervical samples), has gained popularity as
an alternative technique for the collection and preparation
of cytologic specimens from many different sites in the
body, including effusions, with good results.17,18 Con-
versely, some controversial data on the efficacy of LBC
have been contradicted by the cost-effective, time-sparing,
simple application of ancillary techniques (both ICC and
molecular analysis) up to 3 or 4 months on stored LBC
material.1–7
Herein, we describe our 13-year experience with
cytologic samples of serous membrane effusions (pleural
and pericardic samples) that were preserved and prepared
using LBC, and we compare our results with data from
the literature, including conventional cytology series. The
objective of this study was to highlight the importance of
a obtaining a correct cytologic diagnosis with LBC and of
defining the exact, inherent feasibility of using FNAC for
effusions, especially in the presence of positive malignant
results. In addition, we assessed the validity of LBC as a
reliable aid to the application of ancillary techniques (ICC
and molecular analysis) in the analysis of both pleural and
pericardic samples. To the best of our knowledge, this is
the largest series to date of such analyses in pleural and
pericardic effusions.
MATERIALS AND METHODS
We included all pleural and pericardic FNAC samples
that were obtained between January 2000 and December
2013 (N5 3171). All samples were recorded in the Divi-
sion of Anatomic Pathology andHistology of the Catholic
University, “Agostino Gemelli” Hospital (Rome, Italy).
All FNAC procedures were carried out under ultrasound
or computed tomography guidance, mostly by surgeons
and radiologists, and the samples were processed using the
ThinPrep method (ThinPrep 5000; Hologic Inc., Marl-
borough, Mass). All pleural and pericardic effusions were
recorded. Our analyses included 2919 pleural effusions
and 252 pericardic effusions, which are analyzed in detail
below (see Results). Here, we focus our specific attention
and discussion on the suspicious and positive results in
both pleural and pericardic effusions.
The series included 1708 men and 1463 women,
and the median patient age was 48 years (age range, 23-92
years). All aspirations (usually 2 passes for each lesion)
were performed with 21-gauge needles, and no rapid on-
site evaluations of the adequacy of material were done. All
patients had been appropriately informed regarding use of
the LBC method for processing their samples, and all
signed a written informed consent form. Our study
followed the tenants of the Declaration of Helsinki, and
we received internal ethics approval for the study.
All aspirated material was fixed with the hemolytic
and preservative solution Cytolyt (Hologic, Inc.) after
rinsing the needle in this solution. The cells were spun at
1500 rotations per minute (30.289g); then, the sediment
was transferred in PreservCyt solution (Cytyc Corpora-
tion, Marlborough, Mass) to be processed with the T5000
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automated processor according to the manufacturer’s rec-
ommendation (Hologic Inc.). The resulting slide was
fixed in 95% ethanol and stained with Papanicolaou, and
the remaining material was stored in PreservCyt solution
for possible later use in the preparation of additional slides
for further investigations (including both ICC and molec-
ular analyses).
Cytologic diagnoses were primarily considered as
adequate for a cytologic diagnosis or inadequate for a cyto-
logic diagnosis. The former group was subclassified as fol-
lows: 1) negative for malignancy (NM), 2) suspicious for
malignancy (SM), and 3) positive for malignancy (PM).
We also signed out cases with a finding of positive for
malignancy supporting/confirming the primary cancer
diagnosis.
Additional slides for ICC (307 pleural and pericar-
dic malignant samples and all 104 pleural and pericardic
suspicious samples) and/or molecular analysis (47 pleural
samples) were obtained from the material stored in
PreservCyt solution. In these slides, analyses could be
performed even with only 2 mL of remaining material
eluted in 5 mL of PreservCyt solution. The percentage of
disease-specific cells for ICC analysis was at least 30% in
all LBC samples.
ICC
ICC staining was carried out with the avidin-biotin perox-
idase complex using a variety of antibodies based on both
clinical suspicions and the cytologic findings. The slides
were washed 3 times in phosphate-buffered saline (PBS)
and then preincubated in normal veal serum with PBS
(1:50 dilution) for 20 minutes before an overnight incu-
bation at 4C with the primary antibody. Then, the slides
were washed 3 times with PBS and incubated with biotin-
ylated secondary antibody-conjugated avidin-biotin-per-
oxidase complex (Ventana Systems, Tucson, Ariz). The
reaction was developed using 3-30-diaminobenzidine as a
chromogen. All slides were counterstained with hematox-
ylin for 5 seconds, rinsed in water 3 times, then mounted
for microscopic examination. Each cytologic sample was
assessed as positive if 50% of cells had strong cytoplas-
mic or nuclear positivity based on the specific immuno-
marker used. This stringent cutoff percentage was chosen
to avoid false-positive results and was aligned with the
reported staining results from histologic diagnoses. Posi-
tive and negative controls were selectively used according
to each specific immunomarker. Our ICC evaluation was
carried out in 411 of 450 samples (91.3%), including sus-
picious and malignant samples of both pleural and peri-
cardic effusions (for details, see Results, below).
Molecular Analysis
Genomic DNA was extracted from cytologic samples
using a spin column extraction method (QIAamp DNA
mini kit; QIAGEN, Milan, Italy). DNA concentration
and purity were assessed using a NanoDrop 2000c Spec-
trophotometer (Thermo Scientific Inc., Wilmington,
Del). Mutational analysis of epidermal growth factor
receptor (EGFR) was performed using the Therascreen
EGFR RGQ polymerase chain reaction kit (QIAGEN) in
a Rotor-Gene Q 5plex HRM instrument according to the
manufacturer’s protocol (sensitivity, <1%). The muta-
tion nomenclature used in this work follows the guidelines
indicated by the Human Genome Variation Society.19
Histology
All surgical specimens were fixed in 10% buffered formal-
dehyde and embedded in paraffin; then, 5-lm-thick
sections were stained with hematoxylin and eosin. Con-
cordance of ICC results was 100% between the cytologic
and histologic samples.
Statistical Analysis
Statistical analyses were performed using a commercially
available statistical software package (SPSS 10.0; SPSS
Inc., Chicago, Ill) for Windows (Microsoft, Redmond,
Wash). Comparisons of categorical variables were per-
formed using chi-square statistics with the Fisher exact
test when appropriate. All P values< .05 were considered
significant.
RESULTS
Table 1 provides data on the distribution of the 3171
benign and malignant cytologic diagnoses according to
clinical and morphologic features. When matched for sex,
no significant difference was observed, as indicated by the
slightly higher number of men than women (1708 men vs
1463 women).
The samples were distributed based on their diagno-
ses—classified as NM, SM, or PM—for both pleural and
pericardic effusions. The series included 2505 pleural and
216 pericardic NM samples, 93 pleural and 11 pericardic
SM samples, and 321 pleural and 25 pericardic PM sam-
ples (Table 1). Furthermore, 20 samples produced
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inadequate results based on the use of LBC with the possi-
bility of additional slides, so that the combined evaluation
reached a diagnostic and descriptive sign-out in >98% of
the samples analyzed.
The 2505 samples in the pleural NM category did
not produce any false-positive results but did produce 48
false-negative results (1.9%). Samples in the pleural NM
category were characterized by 980 with LBC slides only;
943 with histologic diagnoses, including 677 nonsmall
cell lung carcinomas (NSCLCs), 65 ovarian carcinomas,
and 201 breast carcinomas with negative histologic pleu-
ral involvement; and 582 that had an additional cell block
to combine with the LBC slide for a more accurate mor-
phologic diagnosis. None of these samples underwent any
immunomarker or molecular testing (Table 1). The 216
pleural NM samples did not produce any false-positive
results but did produce 1 false-negative result. Samples in
the pericardic NM group were characterized by 186 with
LBC slides only and 30 with histologic diagnoses, including
16 NSCLCs, 5 ovarian carcinomas, and 9 breast carcinomas
(Fig. 1) with negative histologic pleural involvement.
Among the 414 pleural SM and PM samples, 76
unknown primary malignancies and 338 known primary
carcinomas were reported; whereas, among the 36 pericar-
dic SM and PM samples, 20 unknown primary malignan-
cies and 16 known primary carcinomas were reported, as
detailed for pleural and pericardic effusions in Table 2
and Figure 2.
These latter interesting and challenging categories are
the focus of our discussion and evaluation, as also sup-
ported by the application of ancillary techniques (Table 3).
Considering the application of ICC, which we performed
as an immunopanel rather than as a single immunomarker,
in total, we yielded 375 pleural effusions (all 93 SM sam-
ples and 282 of 321 pleural PM samples) and all SM and
PM pericardic effusions. The ICC panels were carried out
on stored LBCmaterial with 100% conclusive results. ICC
was performed both on stored LBC slides and on cell
Figure 1. This photomicrograph shows the details of a malig-
nant pericardic effusion from a breast carcinoma (Papanico-
laou stain; original magnification 3400).
Table 1. Clinicomorphologic Evaluation in 3171
Pleural and Pericardic Effusions in Liquid-Based
Cytology
Variable NM SM PM
Age range, y 36-79 25-85 33-92
Sex: No. of men/women 1411/1310 67/37 230/116
Group, no. of samples
Pleural effusions 2505a 93 321
Pericardic effusions 216b 11 25
No. of additional cell-block slides 582 104 356
Histology, no. of samples 943 63c 296d
ICC, no. of samples 0 104 307
Abbreviations: ICC, immunocytochemistry; NM, negative for malignancy;
PM, positive for malignancy; SM, suspicious for malignancy.
a Forty-eight positive samples were included.
bOne false-positive sample was included.
c Forty-one unknown samples (36 from the pleural group and 5 from the
pericardic group) were excluded (see Table 2).
d Sixty unknown samples (40 from the pleural group and 20 from the peri-
cardic group) were excluded (see Table 2).
Table 2. Distribution of Pleural and Pericardic
Diagnoses With Histological Findings
Cytologic Diagnoses, No. of Samples
Histologic





Unknown 0 0 36 40 76
Lung Ca 0 24 21 133 128
Ovarian Ca 0 3 13 62 73
Breast Ca 0 11 4 31 32
Gastrointestinal Ca 0 6 9 22 27
Mesothelioma 0 0 5 11 16
Myeloma 0 0 0 3 0
Kidney/urologic Ca 0 4 0 5 5
Lymphoma 0 0 3 11 14
Head and neck Ca 0 0 1 4 4
Pericardic diagnosesb
Unknown 0 0 5 15 20
Lung Ca 0 1c 0 9 9
Ovarian Ca 0 0 0 4 4
Breast Ca 0 0 0 1 1
Lymphoma 0 0 0 1 1
Head and neck Ca 0 0 1 0 1
Abbreviations: Ca, carcinoma; ICC, immunocytochemistry; NM, negative for
malignancy; PM, positive for malignancy; SM, suspicious for malignancy.
aNone of the 48 false-negative pleural samples had ICC.
bData for gastrointestinal, mesothelioma, myeloma, and urologic Ca were
omitted because of the absence of samples.
c The 1 false-negative pericardic sample had no ICC.
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blocks that were obtained from stored LBC material, and
no significant differences in expression were observed.
Table 3 provides data on the distribution of immu-
nomarkers in the SM and PM pleural and pericardic effu-
sions (Figs. 3 and 4). The same table provides an
evaluation of the number of cell-block slides performed
on stored LBC material. In all of our known cases, we
combined LBC slides and cell blocks obtained from stored
LBC material and performed ICC on both. Furthermore,
we reached a conclusive diagnostic report in all 96
unknown cases (70 pleural effusions and 20 pericardic
effusions), although we did not have histologic follow-up.
In addition, we used an extensive ICC panel made
up of epithelial markers, including, ie, keratins 7 and 20,
AE1/AE3 (antipan-cytokeratin antibody), CAM 5.2
(cytokeratin antibody), epithelial-specific antigen, thyroid
trascriptor factor-1 (TTF-1), E-cadherin, and others (see
Table 3); mesenchymal markers (vimentin, desmin, neu-
rofilaments); cluster of differentiation (CD) markers
(CD10, CD15, CD30; and CD45); or other markers
(S100 [calcium-binding protein], carcinoembryonic anti-
gen messenger RNA [mCEA], neuron-specific enolase,
calcitonin, and HMB45 [human melanoma black 45]).
The ICC panels were carried out both in unknown pri-
mary tumor samples and in samples from patients who
had a clinical history of neoplasia.
The assessment of specificity, sensitivity, diagnostic
accuracy, positive predictive value (PPV), and negative
predictive value (NPV) is provided in Table 4. We did
not observe any false-positive results in any of the catego-
ries analyzed; however, there were 49 false-negative
results, including 48 in the NM pleural effusions and 1
in a pericardic effusion. When the pleural and pericardic
effusions were considered together, the results demon-
strated 88% sensitivity, 100% specificity, 98% diagnostic
accuracy, 98% NPV, and 100% PPV. Table 4 also
reports separate data for the pleural and pericardic effu-
sions. Moreover, we used 47 pleural PM effusions for
EGFR mutational analysis based on the diagnosis of
NSCLC and identified 10 with mutations (6 with short
in-frame deletions of exon 19 and 4 with single-
nucleotide substitutions in exon 21 characterized by the
missense leucine to arginine substitution at codon 858
[p.L858R] mutation; data not shown).
DISCUSSION
The results reported here demonstrate the great efficacy of
using cytologic evaluation to ascertain precise diagnoses in
both technical types of sample preparation: smeared sedi-
ment and LBC. Not only does LBC offer some additional
morphologic advantages (clearer background, cell enrich-
ment, and better nuclear details), but residual LBC mate-
rial is also very useful for ancillary methodologies,
including ICC evaluation and molecular tests.5–7,15,16,19 It
is important to highlight this point, because LBC diagno-
ses are comparable to those obtained with traditional
smears and offer a value added in terms of potential use
for additional methodologies, including receptor gene
rearrangements by polymerase chain reaction analysis or
Figure 2. The data concerning diagnoses of suspicious for malignancy and positive for malignancy are summarized in patients
who had pleural and pericardic effusions.
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chromosome translocation by fluorescence in situ hybrid-
ization analysis. All this is critical, because mesothelial cells
can be misinterpreted as neoplasia in certain conditions.
On the basis of our previous, large experience in the
field of FNACwith LBC, we conducted the current analy-
sis in a large series of 3171 pleural and pericardic effusions
that were processed with LBC. The results underscore the
reliability of using cytology to identify positive and suspi-
cious effusions, in which cytology can provide essential
clues for diagnosis and staging regardless of body site.
Although no specific guidelines for the optimal or
best processing of FNAC effusions have been proposed in
recent years, several authors have reported reliable data
with the application of conventional cytology, which has
been the cornerstone of cytologic preparations for many
years.1–8 With this perspective, we have analyzed our
13-year experience using LBC preparations, underscoring
the pros and cons of this method reported in the recent
literature.1–3,9,13
The enthusiasm for LBC has been because of its dif-
ferent advantages, identified mainly as a uniform collec-
tion procedure, avoiding the hazards of needles during
conventional preparations, standardized processing




Malignant Effusions Antibody Tested on Cytologic and Cell-Block Samplesa
Pleural effusions
Unknown 30/46 Positive: 5 vimentin, 5 calretinin, 10 TTF-1, 2 CEA, 10 CAM 5.2M, 6 BER-EP4,
5HBME-1, 15 CD20, 10 CK7, 5 CK20, 1 p63, 2 CK5/6b
Breast Ca 4/28 Positive:CK7, GCDFP15, ER, PR, E-cadherin; negative: TTF-1,calretinin, CK5/6
Lung Ca 21/107 Positive:TTF-1, CAM 5.2, CK7, p63; negative: S100, calretinin, CK5/6
Ovarian Ca 13/60 Positive: CA125, WT1, CAM 5.2, CK7, ER, PR, CEA; negative: S100, CK5/6,
calretinin, CK20, CDX2
Mesothelioma 5/11 Positive: CAM 5.2, calretinin, HBME-1, podoplanin; negative: TTF-1
Gastrointestinal Ca 9/18 Positive: CAM 5.2,CK20, CDX2; negative: TTF-1, calretinin, CK5/6
Lymphoma 3/11 Positive: LCA, CD20, CD79A, CD30, CD15; negative: TTF-1, CAM 5.2, CK20,
CDX2, CK5/6, calretinin
Head and neck Ca 1/3 Positive: EMA, CAM 5.2, AE1/AE3; negative: thyroglobulin, TTF-1, calcitonin,
HBME-1, galectin3
Urogenital Ca 0/5 Positive: EMA, CAM 5.2, vimentin, CD10; negative: thyroglobulin, TTF-1
Pericardic effusions
Unknown 5/15 Positive: 5 vimentin, 1 desmin, 5 calretinin, 10 TTF-1, 2 CEA, 10 CAM 5.2M, 6
BER-EP4, 5 HBME-1, 15 CD20, 10 CK7, 5 CK20, 1 p63, 2 CK5/6b
Breast Ca 0/1 Positive:CK7, GCDFP15, ER, PR, cadherin; negative: TTF-1
Lung Ca 0/9 Positive:TTF-1, CAM 5.2, CK7, p63; negative: S100, calretinin, CK5/6
Ovarian Ca 0/4 Positive: CA 125, WT1, CAM 5.2, CK7, ER, PR; negative: S100
Lymphoma 0/1 Positive: LCA, CD20, CD79A, CD30, CD15; negative: TTF-1, CAM 5.2, CK20,
CDX2, CK5/6, calretinin
Head and neck Ca 1/0 Positive: EMA, CAM 5.2, AE1/AE3; negative: thyroglobulin, TTF-1, calcitonin,
HBME-1, galectin3
Abbreviations: AE1/AE3, antipan-cytokeratin antibody; BER-EP, antiepithelial antigen antibody; CA 125, cancer antigen 125; Ca, carcinoma; CD15, cluster of
differentiation 15, 3-fucosyl-N-acetyl-lactosamine; CD20, cluster of differentiation 20, B-lymphocyte antigen; CD30, cluster of differentiation 30, cell membrane
protein of the tumor necrosis factor receptor family; CD79K, cluster of differentiation 79A molecule, immunoglobulin-associated a; CDX2, caudal type homeo-
box 2; CEA, carcinoembryonic antigen; CK, cytokeratin; CAM 5.2, cytokeratin antibody; EMA, antiendomsial antibody; ER, estrogen receptor; GCDFP-15,
gross cystic disease fluid protein 15; HBME-1, mesothelioma marker antibody; LCA, leukocyte common antigen; p63, tumor protein 63; PR, progesterone
receptor; S100, S100 calcium-binding protein; TTF-1; thyroid transcription factor-1; WT1, Wilms tumor 1.
a Values for positive results are reported, so that the remaining values reflect the corresponding negative values.
b Immunocytochemistry was performed both on stored liquid-based cytology slides and on cell blocks derived from stored liquid-based cytology material, and
there was no significant difference in expression.
Figure 3. This photomicrograph shows a thyroid transcription
factor 1 (TTF-1)-positive pleural effusion from a lung carcinoma
(avidin-biotin-peroxidase complex; original magnification 3400).
Original Article
6 Cancer Cytopathology Month 2015
techniques, the availability of residual material for addi-
tional slides or cell blocks, and the easier application of
ancillary techniques (ICC and molecular test-
ing).1–3,5,6,15,19 Conversely, the limits of LBCmay be rep-
resented by the impossibility of assessing samples for
adequacy or triage, including culture and flow cytometry,
which may represent critical points in some diagnostic sit-
uations.6 In addition, Hoda3 reviewed all of the published
literature on the morphologic aspects of LBC for nongy-
necologic cytology and underscored the accuracy of both
ThinPrep and SurePath for the interpretation of effusions,
in alignment with data published by Ylagan et al.3,10
The first critical role of FNAC in effusions is to
discriminate between benign and malignant disease
and to rule out a diagnosis of benign reactive mesothelial
cells versus adenocarcinoma and epithelial mesothe-
lioma.9,12,13,18,20,21 Indeed, as highlighted by Ylagan et al,
the overlapping cytologic features in some samples may
prevent a more definitive diagnosis, and a panel of immu-
nomarkers is strongly suggested when a cytopathologist
faces this issue.10
Moreover, when analyzing other possible malignant
neoplasms diagnosed in pleural effusions, many associa-
tions may be observed between malignant mesothelioma
and serous carcinoma because of the common histogenesis
and coexpression of the immunomarkers. In our series, we
reported 72 ovarian metastatic carcinomas in which
Wilms tumor-1 was not specific for ruling out the correct
diagnosis, whereas CA 125 combined with other markers
(including keratin 7 and calretinin) had good specificity
for discriminating between ovarian metastatic carcinomas
and mesotheliomas.
In our experience, the hotspot evidence that only 49
negative pleural and pericardic effusions were diagnosed
as malignant (1.5%) underlines the highNPV of cytologic
effusions. This relevant statistical significance maximizes
the role of LBC. In fact, in 572 of 2505 pleural NM effu-
sions that had unequivocal interpretations, we combined
the morphologic evaluations of LBC slides and cell blocks
obtained from stored LBC material, and the results were
concordant in all of the 572 samples that were analyzed;
therefore, in those samples, we did not perform any ICC.
Nevertheless, we are conscious that, according to data
published by Sun et al, results from an immunopanel may
be useful in supporting some “critical” morphologic find-
ings, which can overlap between reactive mesothelial cells
and mesothelioma even among experienced cytopatholog-
ists.13 In addition, although we did not use any immuno-
markers, a growing body of literature is encouraging the
diagnostic value of some immunomarkers (ie, claudin-4
or mucin-1) with high sensitivity and specificity for dis-
criminating between reactive mesothelial cells and meta-
static adenocarcinomas.12,13,22,23
It is important to point out the inadequate rate in
our current results. Our 0.6% nondiagnostic rate for the
pleural NM samples was very low, probably because LBC
offered the ability to prepare additional slides and cell
blocks, with a consequent decrease in the inadequate rate.
Likewise, the nondiagnostic samples were ascribed to the
scant material obtained from aspiration, which also
Figure 4. Positivity for E-cadherin in the same sample (peri-
cardic effusion from a breast carcinoma) from Figure 1 is
observed in a cell-block preparation (avidin-biotin-peroxidase
complex; original magnification 3400).
Table 4. Descriptive Statistics for Morphologic










Sensitivity 88 87 97
Specificity 100 100 100
Diagnostic accuracy 98 98 99
NPV 98 98 99
PPV 100 100 100
Abbreviations: NPV, negative predictive value; PPV, positive predictive
value.
Fine-needle aspiration cytology of serous membrane effusions may fulfill a
challenging role in the diagnostic analysis of both primary and metastatic
disease. In addition, liquid-based cytology is useful for ancillary techniques,
with reliable and feasible yields demonstrated in 3171 cytologic samples.
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rendered it impossible to prepare a second LBC slide or
cell block or to apply any of the ancillary techniques.
Therefore, our finding of a 14.8% malignant rate
for LBC slides is in perfect agreement with the 15%
malignant rate reported by Lee et al on LBC, whereas the
discrepancies with the results from other series are a conse-
quence of differences in preparation and cytohistologic
bias.1,2 Our data on the LBC method are in keeping with
a report by Gabriel et al, who compared 2 series (an LBC
series and a conventional cytology series) without observ-
ing any discrepancies in terms of sensitivity, specificity, or
diagnostic accuracy and concluded that in, body fluid
cytology, LBC may replace other types of preparations
with a lower false-negative rate.8
The well known assessment that malignant effusions
in the pleura and peritoneum are frequently signs of the
metastatic involvement of primary adenocarcinomas, par-
ticularly among women with breast and ovarian cancers
and among both men and women with lung carcinoma, is
in keeping with the current findings.1,2,18,20,21 In fact,
ovarian and breast carcinomas accounted for 72 and 34
malignancies, respectively, in pleural PM and SM samples
and also represented the most frequent primary malignan-
cies in the pericardic samples.
Overall, some original and review articles have
pointed to the application of ICC as well as fluorence in
situ hybridization, comparative genomic hybridization,
and other molecular techniques mainly for 2 clinical sce-
narios: searching for metastatic cells and characterizing
mesothelioma.12–16 Although the application for ancillary
techniques represented a valid aid even in our study, we
assessed the central role of morphology in FNAC for
drawing attention to the performance of a specific useful
panel unless we were testing unknown malignancies.
Although the majority of articles we reviewed produced
feasible results with the application of ICC on conven-
tional cytology or cell-block slides, we encourage the use
of LBC as a valid alternative method for the application of
different, specific ICC panels to additional slides obtained
from the material stored in PreservCyt solution.3,5,6,15,16
Indeed, the findings for >66% of our SM and PM effu-
sions (441 of 450 total malignant effusions) were sup-
ported by ICC applications, including the use of specific
diagnostic immunomarkers in 96 samples from unknown
primary neoplasms, resulting in 100% conclusive results.
Therefore, in the latter 96 samples, the use of an LBC
preparation offered the opportunity to refine and polish
the morphologic description of samples in which mor-
phology alone could no longer achieve a conclusive and
specific malignant diagnosis.
We carried out ICC analyses on both LBC slides
and cell blocks obtained from stored LBC material with-
out observing any discrepancies, in keeping with data
reported by Jing et al, who also explored the role of col-
lecting media in cell block preparations without observing
any interference in the performance of immunostaining.17
Hence, in contrast to the central role played by ICC in
recent years, the emerging role of molecular testing of
effusions has gained new enthusiasm.14
Different cytologic methods did not affect DNA
quality or molecular tests, enforcing the use of LBC
for identifying EGFR mutational expression (including
all mutations in exons 18-21) or anaplastic lymphoma
kinase (ALK) rearrangements in 39 metastatic pleural
effusions from patients with NSCLC, as noted in some
previous reports, including ours.24,25 The increasing
use of LBC for ancillary techniques and in effusions
has widened the classic role of morphologic distinction
between small cell lung carcinomas and NSCLCs with-
out any possible further diagnostic or prognostic impli-
cations. Our current investigation demonstrates the
outstanding role of cytologic specimens in supplying
adequate material not only for diagnosis but also for
gene mutation assays, essentially in EGFR and other
gene mutations or rearrangements (ie, KRAS gene
mutations or ALK rearrangements).25
In the current series, and in agreement with the liter-
ature, we observed that LBC preparations in pleural and
pericardic effusions had 87% sensitivity, 100% specificity,
89% diagnostic accuracy, 98% NPV, and 100% PPV,
which undoubtedly exceeded the average values under-
scored in several series that used conventional cytol-
ogy.2,9,10 In conclusion, to date, this is the largest series of
pleural and pericardic effusions in LBC preparations; and,
based on our findings, we believe that the combined use
of morphologic FNAC evaluation and the application of
both ICC and molecular analyses on LBC preparations is
feasible and reliable and that the combination of mor-
phology and ancillary techniques represents the best strat-
egy, particularly in patients for whom morphology alone
cannot achieve a conclusive diagnosis.
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